Use of 0.12% betamethasone valerate foam vs 0.01% fluocinolone acetonide topical oil to treat scalp psoriasis: Quantitative assessment of patient preference and treatment efficacy

Cosmetic Dermatology

Volumn 15, Issue 11, 2002, Pages 27-30

  Housman, Tamara Salam ^a   McMichael, Amy J ^a   Mellen, Beverly G ^a   Derrow, Amy E ^a   McCarty, Martha A ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETAMETHASONE VALERATE; FLUOCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG PREFERENCE; ERYTHEMA; FOAM DRESSING; HUMAN; PATIENT COMPLIANCE; PSORIASIS; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCALP; TREATMENT OUTCOME;

EID: 0347693566     PISSN: 10413766     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401-407.
2. Krueger GG, Feldman SR, Camisa C, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? what constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43:281-285.
3. Trozak DJ. Topical corticosteroid therapy in psoriasis vulgaris. Cutis. 1990;46:341-350.
4. Rapp SR, Exum ML, Reboussin DM, et al. The physical, psychological and social impact of psoriasis. J Health Psychol. 1997;2:525-537.
5. Piacquadio D, Kligman A. The critical role of the vehicle to therapeutic efficacy and patient compliance. J Am Acad Dermatol. 1998;39:S67-S73.
6. van de Kerkhof PC, Steegers-Theunissen RP, Kuipers MV. Evaluation of topical drug treatment in psoriasis. Dermatology. 1998;197:31-36.
7. Dunlap FE, Mills OH, Tuley MR, et al. Adapalene 0.1% gel for the treatment of acne vulgaris: its superiority compared to tretinoin 0.025% cream in skin tolerance and patient preference. Br J Dermatol. 1998;139:17-22.
8. Housman TS, Meilen BG, Rapp SR, et al. Psoriasis patients prefer solution and foam vehicles: a quantitative assessment of vehicle preference (in press).
9. Poyner TF, Menday AP, Williams ZV. Patient attitudes to topical antipsoriatic treatment with calcipotriol and dithranol. Eur J Dermatol. 2000;14:153-158.
10. Stoughton RB. Are generic formulations equivalent to trade name topical glucocorticoids? Arch Dermatol. 1987;123:1312-1314.
11. Drug Topics Red Book. Montvale, NJ: Medical Economics; 2001:273, 392.